Use of a Baculovirus-Mammalian Cell Expression-System for Expression of Drug-Metabolizing Enzymes: Optimization of Infection With a Focus on Cytochrome P450 3A4.

UDP-glucuronosyltransferase bac-mam system baculovirus cytochrome P450 3A4 drug-metabolizing enzyme heterologous expression mammalian cell

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2022
Historique:
received: 10 12 2021
accepted: 28 01 2022
entrez: 17 3 2022
pubmed: 18 3 2022
medline: 18 3 2022
Statut: epublish

Résumé

Heterologous expression systems are important for analyzing the effects of genetic factors including single nucleotide polymorphisms on the functions of drug-metabolizing enzymes. In this study, we focused on a baculovirus-mammalian cell (Bac-Mam) expression system as a safer and more efficient approach for this purpose. The baculovirus-insect cell expression system is widely utilized in large-scale protein expression. Baculovirus has been shown to also infect certain mammalian cells, although the virus only replicates in insect cells. With this knowledge, baculovirus is now being applied in a mammalian expression system called the Bac-Mam system wherein a gene-modified baculovirus is used whose promotor is replaced with one that can function in mammalian cells. We subcloned open-reading frames of cytochrome P450 3A4 (CYP3A4), UDP-glucuronosyltransferase (UGT) 1A1, and UGT2B7 into a transfer plasmid for the Bac-Mam system, and prepared recombinant Bac-Mam virus. The obtained virus was amplified in insect Sf9 cells and used to infect mammalian COS-1 cells. Expression of CYP3A4, UGT1A1, and UGT2B7 in COS-1 cell homogenates were confirmed by immunoblotting. Optimum infection conditions including the amount of Bac-Mam virus, culture days before collection, and concentration of sodium butyrate, an enhancer of viral-transduction were determined by monitoring CYP3A4 expression. Expressed CYP3A4 showed appropriate activity without supplying hemin/5-aminolevulinic acid or co-expressing with NADPH-cytochrome P450 reductase. Further, we compared gene transfer efficiency between the Bac-Mam system and an established method using recombinant plasmid and transfection reagent. Our results indicate that the Bac-Mam system can be applied to introduce drug-metabolizing enzyme genes into mammalian cells that are widely used in drug metabolism research. The expressed enzymes are expected to undergo appropriate post-translational modification as they are in mammalian bodies. The Bac-Mam system may thus accelerate pharmacogenetics and pharmacogenomics research.

Identifiants

pubmed: 35295333
doi: 10.3389/fphar.2022.832931
pii: 832931
pmc: PMC8919721
doi:

Types de publication

Journal Article

Langues

eng

Pagination

832931

Informations de copyright

Copyright © 2022 Miyauchi, Kimura, Sawai, Fujimoto, Hirota, Tanaka, Takechi, Mackenzie and Ishii.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Front Pharmacol. 2016 Nov 14;7:427
pubmed: 27895582
Biochem Biophys Res Commun. 1990 Feb 14;166(3):1293-9
pubmed: 2106315
Drug Metab Dispos. 2012 Oct;40(10):1935-44
pubmed: 22782802
Arch Biochem Biophys. 1999 Jul 1;367(1):129-36
pubmed: 10375408
Pharmacol Ther. 1999 Nov;84(2):121-31
pubmed: 10596902
Acta Pharmacol Sin. 2005 Apr;26(4):405-16
pubmed: 15780188
Biol Chem. 2001 Feb;382(2):151-9
pubmed: 11308014
Drug Metab Dispos. 2014 Feb;42(2):229-38
pubmed: 24255116
Science. 1999 Oct 15;286(5439):487-91
pubmed: 10521338
Nucleic Acids Res. 1983 Nov 11;11(21):7631-48
pubmed: 6316266
Mol Cell Biochem. 1982 Feb 5;42(2):65-82
pubmed: 6174854
Pharmacol Ther. 2003 May;98(2):221-33
pubmed: 12725870
Mol Pharmacol. 2015 Oct;88(4):800-12
pubmed: 26243732
Pharmacogenomics J. 2002;2(1):48-56
pubmed: 11990382
Adv Pharm Bull. 2013;3(2):257-63
pubmed: 24312845
Biochem Biophys Res Commun. 2020 Apr 30;525(2):348-353
pubmed: 32093886
Drug Metab Pharmacokinet. 2009;24(3):209-17
pubmed: 19571432
Structure. 2016 May 3;24(5):797-805
pubmed: 27041595
Biochem Pharmacol. 2010 Apr 15;79(8):1165-72
pubmed: 19951703
AAPS J. 2006 Mar 10;8(1):E101-11
pubmed: 16584116
Arch Biochem Biophys. 1989 Nov 1;274(2):481-90
pubmed: 2679389
Biol Pharm Bull. 2021;44(11):1635-1644
pubmed: 34719641
Virology. 2001 Jan 5;279(1):343-53
pubmed: 11145915
Drug Metab Pharmacokinet. 2020 Oct;35(5):466-474
pubmed: 32883578
Biochemistry. 2000 Sep 26;39(38):11540-52
pubmed: 10995221
Pharmacol Ther. 2013 Apr;138(1):103-41
pubmed: 23333322
Curr Opin Biotechnol. 1993 Oct;4(5):564-72
pubmed: 7764207
J Biol Chem. 1964 Jul;239:2370-8
pubmed: 14209971
Virology. 2003 May 25;310(1):1-7
pubmed: 12788624
Appl Environ Microbiol. 1983 Mar;45(3):1085-93
pubmed: 16346229
Methods Enzymol. 1991;206:100-8
pubmed: 1784200
Drug Metab Pharmacokinet. 2013;28(2):83-92
pubmed: 23089802
Cytotechnology. 2002 Jan;38(1-3):37-41
pubmed: 19003084
Cell. 1981 Jan;23(1):175-82
pubmed: 6260373
J Biol Chem. 1986 Oct 25;261(30):14112-7
pubmed: 2429951
Drug Metab Rev. 2010 Feb;42(1):145-58
pubmed: 19817679
Curr Drug Metab. 2008 Jan;9(1):70-6
pubmed: 18220573
Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10099-103
pubmed: 7479733
Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2348-52
pubmed: 8637876
J Gene Med. 1999 Mar-Apr;1(2):93-102
pubmed: 10738573
Oncol Rep. 2012 Apr;27(4):1111-5
pubmed: 22160140
Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):127-32
pubmed: 9874783
Sci Rep. 2020 Aug 25;10(1):14193
pubmed: 32843676
Drug Metab Dispos. 2012 Aug;40(8):1620-7
pubmed: 22619308
Drug Metab Rev. 2010 Feb;42(1):209-24
pubmed: 19821798
Drug Metab Pharmacokinet. 2012;27(4):388-97
pubmed: 22240840
Viruses. 2015 Apr 22;7(4):2099-125
pubmed: 25912715
Drug Metab Dispos. 1997 Nov;25(11):1234-41
pubmed: 9351898

Auteurs

Yuu Miyauchi (Y)

Laboratory of Hygienic Chemistry, Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan.
Division of Pharmaceutical Cell Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

Akane Kimura (A)

Division of Pharmaceutical Cell Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

Madoka Sawai (M)

Laboratory of Hygienic Chemistry, Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan.

Keiko Fujimoto (K)

Division of Pharmaceutical Cell Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

Yuko Hirota (Y)

Division of Pharmaceutical Cell Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

Yoshitaka Tanaka (Y)

Division of Pharmaceutical Cell Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

Shinji Takechi (S)

Laboratory of Hygienic Chemistry, Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan.

Peter I Mackenzie (PI)

Clinical Pharmacology, College of Medicine and Public Health, Flinders Medical Centre and Flinders University, Adelaide, SA, Australia.

Yuji Ishii (Y)

Division of Pharmaceutical Cell Biology, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

Classifications MeSH